CAMX.ST Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (31 geg. 2024 @ 18:29):

Camurus AB (publ), a pharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, Japan, and internationally...

Stats
Šios dienos apimtis	402 963
Vidutinė apimtis	83 050.00
Rinkos kapitalizacija	33.48B
EPS	SEK0 ( 2024-05-07 )
Kita pelno data	( SEK1.260 ) 2024-07-16
Last Dividend	SEK0 ( N/A )
Next Dividend	SEK0 ( N/A )
P/E	74.58
ATR14	SEK1.373 (0.24%)

Tūris Koreliacija

Ilgas: -0.22 (neutral)

Trumpas: -0.34 (neutral)

Signal:(69.761) Neutral

Camurus AB (publ) Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Camurus AB (publ) Koreliacija - Valiuta/Žaliavos

0.82
( strong )

0.76
( moderate )

0.27
( neutral )

0.49
( neutral )

0.15
( neutral )

0.56
( weak )

Camurus AB (publ) Finansinės ataskaitos

Annual	2023
Pajamos:	SEK1.72B
Bruto pelnas:	SEK1.58B (92.06 %)
EPS:	SEK7.78

FY	2023
Pajamos:	SEK1.72B
Bruto pelnas:	SEK1.58B (92.06 %)
EPS:	SEK7.78

FY	2022
Pajamos:	SEK956.34M
Bruto pelnas:	SEK853.08M (89.20 %)
EPS:	SEK1.010

FY	2021
Pajamos:	SEK600.57M
Bruto pelnas:	SEK515.22M (85.79 %)
EPS:	SEK-1.660

Financial Reports:

No articles found.

Camurus AB (publ) Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Camurus AB (publ)

Camurus AB (publ), a pharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, Japan, and internationally. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence; episil oral liquid, a medical device for the treatment of inflammatory and painful conditions in the oral cavity; and Brixadi to treat opioid use disorder Its products pipeline also includes CAM2038 for the treatment of chronic pain; CAM2029, which is in phase III clinical trials for the treatment of acromegaly and neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 that is in phase I clinical trial for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trial to treat Raynaud's phenomenon. In addition, the company is developing CAM2032, which is in phase II clinical trials for the treatment of prostate cancer; CAM4072 that is in phase III clinical trials for the treatment of genetic obesity disorders; CAM4071, which is in phase I clinical trials for the treatment of endocrine disorder; CAM2047 for the treatment of chemotherapy-induced nausea and vomiting that is in phase 1 clinical trial; and CAM2048, which is in phase I clinical trial for postoperative pain. Camurus AB (publ) was founded in 1991 and is headquartered in Lund, Sweden.